13 August 2024
IQ-AI Limited (the "Company" or the
"Group")
Half Yearly Report for the Period Ended
30 June 2024
The Board of IQ-AI Ltd is pleased to announce
the Company's half yearly report for the period ended 30 June
2024.
For further information, please
contact:
IQ-AI
Limited
Trevor Brown/Vinod Kaushal/Brett
Skelly
|
+44 (0)207 469 0930
|
Peterhouse
Capital Limited
Lucy Williams/Heena Karani
|
+44 (0)207 220 9797
|
Chief
Executive's Statement
Financial
Highlights
- First half revenue was £444,000, an increase
of 57% over the comparable period in 2023.
- Net
assets have increased from £94,924 as of 31 December 2023 to
£433,188 as of 30 June 2024.
Phase 1
Clinical Trial (IB003, gallium maltolate)
The trial is in its final stages. As soon as
all the results are available, an End of Phase 1 ("EOP1") meeting
will be held with the US Food and Drug Administration ("FDA"). The
EOP1 meeting is critical. In an FDA Fast Track Designated
development program, FDA resources are assigned to help abbreviate
various aspects of the development pathway, including offering
strategic guidance for the phase 2 protocol that is currently being
drafted. We anticipate this will happen before the end of this
year.
Since receiving FDA approval to proceed with
the EAP, 32 patients have expressed an interest in participating.
We are working closely with eligible patients to help them navigate
the on-boarding process and we are providing resources and
information to help them cover the costs of the EAP. We are waiting
for various sites across the US to obtain final administrative
approval and anticipate the first site to become active in late
August.
The development of IB003 and the EAP remain our
priority. We are continually exploring how we can further utilise
the regulatory milestones achieved last year (our two Orphan Drug
and two Rare Paediatric Disease Designations). Data from a phase 2
trial will be represent a significant step towards having an
approved agent. If granted approval by the FDA, the Directors
believe that the ensuing commercial impact would be significant for
IQAI.
IB
Clinic
We will be introducing the next software
release of IB Clinic later in Q3. This release includes important
new features and enhancements requested by current and prospective
clients, along with some necessary upgrades in cybersecurity and
general updates to the code base. Of most significance, will be the
ability to post-process Spin and Gradient Echo ("SAGE") data. This
development is the result of funding provided by the National
Institutes of Health ("NIH") under a multi-centre grant. To our
knowledge, we will be the first company to offer SAGE processing.
An enhancement to IB Neuro, it will be the only processing
application built upon a cross-vendor effort to implement SAGE.
SAGE permits the collection of rCBV information with a variable
sensitivity to vessels of different diameters, as well as
additional tissue biophysical metrics relevant to changes observed
with cancer and treatment and represents the future of perfusion
MRI.
In parallel with the next release, we will be
offering an artificial intelligence (AI) based pipeline that
enables the automatic generation of quantitative perfusion class
maps (also known as "FTB" or fractional tumour burden). This
long-awaited and highly demanded feature eliminates the need for an
end user, such as a neuroradiologist or skilled MR technologist,
from performing a manual segmentation step. As more and more groups
are reporting, FTB maps are demonstrating direct clinical benefit
in terms of diagnostic and treatment assessment capabilities, as
well as heightening inter-reader confidence. Our channel partners
are anxiously waiting for the imminent release of this automated
pipeline as their platforms only support fully automated
applications.
An exciting new application of our quantitative
imaging capabilities is using Delta T1™ maps for assessing the
extent of surgical resection using laser interstitial thermal
therapy ("LITT"). Essentially, Delta T1 maps can intraoperatively
assessment whether neurosurgeons have removed the viable tumour
tissue. It is well acknowledged that the removal of tumour tissue
directly correlates with Overall Survival.
In development is the launch of a new product
development program to process arterial spin labelling ("ASL")
data. ASL is an MR perfusion technique that uses no exogenous
contrast agent. Instead, it tags the patient's own blood which then
acts as the contrast medium during MRI exams. While not as commonly
accepted as the technology contained in IB Neuro, IB ASL™ offers
potential application into new pathologies (such as Alzheimer,
epilepsy, and infectious diseases) and populations. For example,
children who require follow-up imaging or people who may have
adverse reactions to gadolinium-based contrast agents find ASL an
attractive imaging modality.
IB
Nimble
Development work is nearing completion. The
remaining work packages concern the homogenization of the legacy IB
Nimble code base into a single, robust platform that is compatible
with both Android and iOS, and the ability to view medical images
directly on the mobile app. This work is expected to be completed
in late Q1 2025, but discussions are already underway with multiple
new cancer centres who are interested in adopting IB Nimble for
metastatic brain cancer. Ultimately, cancer centres across the
world who adopt IB Nimble will benefit from what could conceivably
be the world's largest repository of mineable healthcare data and
outcomes. While this will take some time to populate, our vision
for this potentially huge source of imaging data presents
significant benefits for predicting health outcomes, improving
accuracy, personalizing medicine, boosting operational efficiency,
continuing research and development, and addressing health
disparities across patient populations.
Outlook
Our diversified product portfolio continues to
evolve and proliferate. While the basic message may now be familiar
to shareholders, the directors believe that the years of sustained
development and innovation will, in due course, yield positive
results for the Company.
Trevor Brown
Chief Executive
Results for the
2024 interim financial period
A summary of the key financial results is set
out in the table below:
|
30 June 2024
|
|
£
|
Revenue
|
444,247
|
Gross
Profit
|
442,200
|
Operating
expenses
|
(716,919)
|
Finance
costs
|
410
|
Loss for the period
from discontinued operations
|
-
|
Loss for the period
|
(274,309)
|
Interest
The net interest cost for the Group for the
period was (£410) (2023: £5,311).
Loss before tax
Loss before tax for the period was £274,309,
which includes a Share Based Payment expense of £259,081 (2023:
£300,473).
Taxation
Taxation charge was £nil for the period (2023:
£nil).
Earnings per share
Basic and diluted earnings per share for the
period were 0.13p loss (2023: 0.16p loss).
Financial position
The Group's balance sheet as at 30 June 2024 can
be summarised as set out in the table below:
|
Net assets
£'m
|
|
£
|
Non-current
assets
|
639,150
|
Net current
liabilities
|
(205,962)
|
Net assets and total
equity
|
433,188
|
Cash flow
Net cash inflow for the period was £47,368
(2023: £223,779 outflow).
Consolidated Income
Statement
For the six months ended 30 June
2024
|
Half year ended
|
(Audited) Full year
ended
|
Half year
ended
|
|
30 Jun 2024
|
31 Dec
2023
|
30 Jun
2023
|
|
£
|
£
|
£
|
Continuing operations
|
|
|
|
Revenue
|
444,247
|
609,390
|
282,652
|
Cost of
sales
|
(2,047)
|
(11,636)
|
(4,042)
|
Gross profit
|
442,200
|
597,754
|
278,610
|
|
|
|
|
Administrative
expenses
|
(716,921)
|
(1,004,086)
|
(573,777)
|
Other
income
|
2
|
8
|
5
|
Operating
loss
|
(274,719)
|
(406,324)
|
(295,162)
|
Impairment of goodwill
and intangible assets
|
-
|
(207,627)
|
-
|
Finance
costs
|
410
|
(9,865)
|
(5,311)
|
Loss before income
tax
|
(274,309)
|
(623,816)
|
(300,473)
|
Income tax
|
-
|
-
|
-
|
Loss for the year from continuing
operations
|
(274,309)
|
(623,816)
|
(300,473)
|
|
|
|
|
Discontinued
operations
|
|
|
|
Loss for the period
from discontinued operations
|
-
|
-
|
-
|
|
|
|
|
Loss for the year attributable to owners
of the Company
|
(274,309)
|
(623,816)
|
(300,473)
|
|
|
|
|
Earnings per share attributable to
owners of the Company
|
|
|
|
From continuing
operations:
|
|
|
|
Basic & diluted
(pence per share)
|
(0.13)
|
(0.34)
|
(0.16)
|
From discontinued
operations:
|
|
|
|
Basic & diluted
(pence per share)
|
(0.00)
|
(0.00)
|
(0.00)
|
|
|
|
|
Total earnings per
share (pence per share)
|
(0.13)
|
(0.34)
|
(0.16)
|
Consolidated Statement of
Comprehensive Income
For the six months ended 30 June
2024
|
Half year
ended
|
(Audited) Full year
ended
|
Half year
ended
|
|
30 Jun 2024
|
31 Dec
2023
|
30 Jun
2023
|
|
£
|
£
|
£
|
Loss for the
period
|
(274,309)
|
(623,816)
|
(300,473)
|
|
|
|
|
Other comprehensive
income
|
|
|
|
Items that may be subsequently
reclassified as profit or loss
|
|
|
|
Exchange differences
on translation of foreign operations
|
39
|
(3,100)
|
3,241
|
|
|
|
|
Total comprehensive loss for the year
attributable to the owners of the Company
|
(274,270)
|
(626,916)
|
(297,232)
|
|
|
|
|
Total comprehensive
loss for year arises from:
|
|
|
|
Continuing
operations
|
(274,270)
|
(626,916)
|
(297,232)
|
Discontinuing
operations
|
-
|
-
|
-
|
|
(274,270)
|
(626,916)
|
(297,232)
|
Consolidated Balance
Sheet
As at 30 June 2024
|
30 Jun 2024
£
|
(Audited)
31 Dec
2023
£
|
30 Jun
2023
£
|
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and
equipment
|
1,050
|
1,677
|
2,867
|
Goodwill
|
71,904
|
71,420
|
214,044
|
Intangible
assets
|
566,196
|
340,870
|
452,588
|
Total non-current
assets
|
639,150
|
413,967
|
669,499
|
|
|
|
|
Current assets
|
|
|
|
Trade and other
receivables
|
249,463
|
168,018
|
355,520
|
Cash
|
186,119
|
138,751
|
90,206
|
Assets classified as
held for sale
|
-
|
-
|
-
|
Total current assets
|
435,582
|
306,769
|
445,727
|
|
|
|
|
Current liabilities
|
|
|
|
Trade and other
payables
|
641,544
|
625,812
|
699,151
|
Liabilities directly
associated with assets classified as held for sale
|
-
|
-
|
-
|
Total current
liabilities
|
641,544
|
625,812
|
699,151
|
|
|
|
|
Net current
assets/(liabilities)
|
(205,962)
|
(319,043)
|
(253,424)
|
NET ASSETS
|
433,188
|
94,924
|
416,075
|
|
|
|
|
Equity
|
|
|
|
Share
capital
|
2,217,098
|
1,906,715
|
1,826,214
|
Share
premium
|
20,705,137
|
20,555,087
|
20,553,499
|
Capital redemption
reserve
|
23,616
|
23,616
|
23,616
|
Merger
reserve
|
160,000
|
160,000
|
160,000
|
Convertible loan note
reserve
|
-
|
100,953
|
223,095
|
Share based payment
reserve
|
340,777
|
81,696
|
81,696
|
Foreign currency
reserve
|
16,878
|
22,866
|
25,228
|
Retained
losses
|
(23,030,318)
|
(22,756,009)
|
(22,477,273)
|
Equity attributable to owners of the
Company
|
433,188
|
94,924
|
416,075
|
|
|
|
|
TOTAL EQUITY
|
433,188
|
94,924
|
416,075
|
Consolidated Cash Flow Statement
For the six months ended 30 June 2024
|
Half year ended
30 Jun 2024
|
(Audited) Full year
ended
31 Dec
2023
|
Half year
ended
30 Jun
2023
|
|
£
|
£
|
£
|
Cash flows
from operating activities:
|
|
|
|
Operating
loss
|
(274,309)
|
(623,816)
|
(300,473)
|
Adjustment
for:
|
|
|
|
Depreciation and
amortisation
|
22,064
|
115,401
|
53,790
|
Impairment of
intangible assets
|
-
|
207,627
|
-
|
Share based payment
expense
|
259,082
|
-
|
-
|
Foreign exchange
loss/(gain)
|
(10,305)
|
37,338
|
37,197
|
Finance
costs
|
(410)
|
9,865
|
5,311
|
(Increase)/Decrease in
receivables
|
(81,446)
|
29,254
|
(158,247)
|
Increase in
payables
|
15,732
|
127,502
|
138,643
|
|
|
|
|
Net cash used in operating
activities
|
(69,592)
|
(96,829)
|
(223,779)
|
|
|
|
|
Cash flows from investing
activities
|
|
|
|
Purchase of
equipment
|
-
|
-
|
-
|
Purchase of intangible
assets
|
(242,930)
|
(78,405)
|
-
|
|
|
|
|
Net cash used in investing
activities
|
(242,930)
|
(78,405)
|
-
|
|
|
|
|
Cash flows from financing
activities
|
|
|
|
Funds raised from
shares issued
|
371,000
|
-
|
-
|
Cost of shares
issued
|
(11,110)
|
-
|
-
|
|
|
|
|
Net cash from financing
activities
|
359,890
|
-
|
-
|
|
|
|
|
Net increase/(decrease) in cash and cash
equivalents
|
47,368
|
(175,234)
|
(223,779)
|
Cash and cash
equivalents brought forward
|
138,751
|
313,985
|
313,985
|
Effects of exchange
rate changes on cash and cash equivalents
|
-
|
-
|
-
|
Cash and cash equivalents carried
forward
|
186,119
|
138,751
|
90,206
|
Summary of significant
accounting policies
IQ-AI Limited (the "Company") is a
limited liability company incorporated and domiciled in
Jersey.
The financial statements are
presented in pounds sterling (£) since that is the currency of the
primary environment in which the Group and Company
operates.
The principal accounting policies
applied in the preparation of these financial statements are set
out below. These policies have been consistently applied to all the
years presented, unless otherwise stated.
Basis of preparation
These financial statements have been
prepared and approved by the Directors in accordance with
International Financial Reporting Standards (IFRS) and IFRIC
interpretations (IFRS IC) as adopted by the European
Union.
The financial statements have been prepared
under the historical cost convention, as modified for the assets
held for sale measured at fair value less costs to sell.
The preparation of financial statements in
conformity with IFRS requires the use of certain critical
accounting estimates. It also requires management to exercise its
judgement in the process of applying the accounting policies.
The areas involving a higher degree of judgement or
complexity, or areas where assumptions and estimates are
significant to the financial statements, are disclosed under the
heading 'Critical accounting estimates and judgements'
below.
Going concern
The Group's business activities, together with
the factors likely to affect its future development, performance
and position are set out in the Chief Executive Officer's
Statement.
The current economic conditions continue to
create uncertainty, particularly over (a) the level of demand for
the group's products; and (b) the availability of finance for the
foreseeable future. The group's forecasts and projections,
taking account of reasonably possible changes in trading
performance, show that additional funding will be required either
via an issue of equity or through the issuance of convertible loan
notes. The Directors are reasonably confident that funds will be
forthcoming if and when they are required. The Chief
Executive Officer has provided a letter of financial support to the
Group to make sufficient funds available, if required, to ensure
the Group can meet its obligations over the going concern
period.
Taking in to account the comments above, the
Directors have, at the time of approving the financial statements,
a reasonable expectation that the Company and the Group have
adequate resources to continue in operational existence for the
foreseeable future. Therefore, they continue to adopt the going
concern basis of accounting in preparing the financial
statements
New
standards, amendments and interpretations adopted by the Group and
Company
The following IFRS or IFRIC interpretations
were effective for the first time for the financial year beginning
1 January 2023. Their adoption has not had any material impact on
the disclosures or on the amounts reported in these financial
statements:
Standards /interpretations
|
Application
|
IAS 1 amendments
|
Presentation and Classification of Liabilities
as Current or Non current
|
IAS 16 Amendments
|
Lease liability in a sale and
leaseback
|
IAS 1 Amendments
|
Presentation of Financial Statements
|
New
standards, amendments and interpretations not yet
adopted
Standards /interpretations
|
Application
|
There are no IFRS's or IFRIC
interpretations that are not yet effective that would be expected
to have a material impact on the Company or Group.
Basis of consolidation
The Group financial statements
consolidate the financial statements of the Company and all its
subsidiaries ("the Group"). Subsidiaries include all entities over
which the Group is exposed, or has rights, to variable returns from
its involvement with the investee and has the ability to affect
those returns through its power over the investee. The existence and effect of potential voting
rights that are currently exercisable or convertible are considered
when assessing whether the Group controls another entity.
Subsidiaries are consolidated from the date on which control
commences until the date that control ceases. Intra-group balances
and any unrealised gains and losses on income or expenses arising
from intra-group transactions, are eliminated in preparing the
consolidated financial statements.
The acquisition method of accounting
is used to account for business combinations. The cost of an
acquisition is measured as the fair value of the assets given,
equity instruments issued, and liabilities incurred or assumed at
the date of exchange, and the equity interests issued. Identifiable
assets acquired, and liabilities and contingent liabilities assumed
in a business combination are measured initially at their fair
value at the acquisition date. Acquisition related costs are
expensed as incurred. Where necessary, amounts reported by
subsidiaries have been adjusted to conform with the Group's
accounting policies.
Investments in subsidiaries
Investments in subsidiaries are held at cost
less any impairment.
Goodwill
Goodwill on acquisition of
subsidiaries represents the excess of the cost of acquisition over
the fair value of the Group's share of the
identifiable net assets and contingent liabilities acquired.
Identifiable assets are those which can be sold separately, or
which arise from legal rights regardless of whether those rights
are separable. Goodwill on acquisition of subsidiaries is included
in intangible assets. Goodwill is not amortised but is tested
annually, or when trigger events occur, for impairment and is
carried at cost less accumulated impairment losses.
Segment reporting
An operating segment is a component
of the Group that engages in business activity from which it may
earn revenues and incur expenses, including revenues and expenses
that relate to transactions with and of the Group's other
components. All operating segments' operating results, for which
discrete financial information is available, are reviewed regularly
by the Group's Board to make decisions about resources to be
allocated to the segment and assess its performance. As a result of
the acquisition during the year, the Group reports on a two-segment
basis - holding company expenses and medical software.
Foreign Currency Translation
Foreign currency transactions are
translated into the functional currency using the exchange rates
prevailing at the dates of the transactions. Foreign exchange gains
and losses resulting from the settlement of such transactions and
from the translation at year-end exchange rates of monetary assets
and liabilities denominated in foreign currencies are recognised in
the income statement. Foreign exchange gains and losses are
presented in the income statement within 'finance income or
costs.'
The results and financial position
of Group entities that have a functional currency different from
the presentation currency are translated into the presentation
currency as follows:
·
assets and liabilities for each Statement of
Financial Position presented are translated at the closing rate at
the date of that Statement of Financial Position;
·
income and expenses for each Income Statement
presented are translated at average exchange rates (unless this
average is not a reasonable approximation of the cumulative effect
of the rates prevailing on the transaction dates, in which case
income and expenses are translated at the rate on the dates of the
transactions); and
·
all resulting exchange differences are recognised
in other comprehensive income.
Goodwill and fair value adjustments
arising on the acquisition of a foreign entity are treated as
assets and liabilities of the foreign entity and translated at the
closing rate. Exchange differences arising are recognised in other
comprehensive income.
Intangible Assets - Intellectual property and internally
generated software
Separately acquired intellectual
property is shown at historic cost. Intellectual property acquired
in a business combination is recognised at fair value at the
acquisition date. Amortisation is calculated using the
straight-line method over the estimated useful life of up to 5
years.
Development costs that are directly
attributable to the design and testing of identifiable and unique
software products controlled by the Group are recognised as
intangible assets when the following criteria are met:
·
it is technically feasible to complete the
software product so that it will be available for use;
·
management intends to complete the software
product and use or sell it;
·
there is an ability to use or sell the software
product;
·
it can be demonstrated how the software product
will generate probable future economic benefits;
·
adequate technical, financial and other resources
to complete the development and use or sell the software product
are available; and
·
the expenditure attributable to the software
product during its development can be reliably measured.
Directly attributable costs that are
capitalised as part of the software product include the software
development employee costs and an appropriate portion of relevant
overheads.
Other development expenditure that
does not meet these criteria is recognised as an expense as
incurred.
Development costs previously
recognised as an expense are not recognised as an asset in a
subsequent period.
Software development costs
recognised as assets are amortised over their estimated useful
lives, which do not exceed 5 years. Amortisation commences when
regulatory approval is obtained, and the product is commercially
available.
Impairment of Non-Financial Assets
Intangible assets that have an
indefinite useful life or intangible assets not ready to use are
not subject to amortisation and are tested annually for impairment.
Assets that are subject to amortisation are reviewed for impairment
whenever events or changes in circumstances indicate that the
carrying amount may not be recoverable. An impairment loss is
recognised for the amount by which the asset's carrying amount
exceeds its recoverable amount. The recoverable amount is the
higher of an asset's fair value less costs of disposal and value in
use. For the purposes of assessing impairment, assets are grouped
at the lowest levels for which there are largely independent cash
inflows (cash-generating units). Prior impairments of non-financial
assets (other than goodwill) are reviewed for possible reversal at
each reporting date.
Financial instruments
Financial assets and financial liabilities are
recognised in the Group's balance sheet when the Group becomes a
party to the contractual provisions of the instrument.
Financial assets
The Group classifies its financial
assets in the following categories financial assets as "at fair
value through profit and loss" and "loans and receivables".
The classification depends on the nature and purpose of the
financial assets and is determined at the time of initial
recognition. Management determines the classification of its
financial assets at initial recognition.
Loans and receivables
Trade receivables are amounts due
from customers for merchandise sold or services performed in the
ordinary course of business. Trade receivables are held with the
objective of collecting the contractual cash flows. If collection
is expected in one year or less (or in the normal operating cycle
of the business if longer), they are classified as current assets.
If not, they are presented as non-current assets.
Trade receivables are recognised
initially at fair value, and subsequently measured at amortised
cost using the effective interest method, less provision for
impairment. The Group applies the IFRS 9 simplified approach to
measuring expected credit losses which uses a lifetime expected
loss allowance for all trade receivables and contract
assets.
Due to the short-term nature of the
other current receivables, their carrying amount is considered to
be the same as their fair value.
A financial asset is assessed at
each reporting date to determine whether there is any evidence that
it is impaired. A financial asset is considered impaired if
objective evidence indicates that one or more events have had a
negative effect on the estimated future cash flows of that asset.
Individual significant financial assets are tested for
impairment on an individual basis. The remaining financial assets
are assessed collectively in groups that share similar credit risk
characteristics. All impairment losses are recognised in the
consolidated income statement.
Cash and cash equivalents
Cash and cash equivalents include
cash in hand, deposits held at call with banks and other short-term
highly liquid investments with maturities of three months or less.
In the consolidated Statement of Financial Position, bank
overdrafts are shown within borrowings in current
liabilities.
Financial liabilities and equity instruments issued by the
group
Financial liabilities and equity instruments
are classified according to the substance of the contractual
arrangements entered into. An equity instrument is any contract
that evidences a residual interest in the assets of the Group after
deducting all of its liabilities. Equity instruments issued by the
Group are recorded at the proceeds received, net of direct issued
costs.
Non-Current Assets (or Disposal Groups) Held-for-Sale and
discontinued operations
Non-current assets (or disposal groups) are
classified as assets held for sale when their carrying amount is to
be recovered principally through a sale transaction and a sale is
considered highly probable. They are stated at the lower of
carrying amount and fair value less costs to sell. A discontinued
operation is a component of the Group that is classified as held
for sale and that represents a separate line of business or
geographical area of operations. The results of discontinued
operations are presented separately in the Consolidated Income
Statement.
Convertible loan notes
The convertible loan note ("CLN") is a compound
financial instrument that can be converted to share capital at the
option of the holder. As the CLN, and the accrued interest, can
only be repaid by the issue of shares, it has been recognised in
equity only, with no liability component. Interest is accounted for
on an accruals basis and charged to the Consolidated Income
Statement and added to the carrying amount of the equity component
of the CLN.
Trade and other payables
Trade payables are obligations to
pay for goods or services that have been acquired in the ordinary
course of business from suppliers. Accounts payable are
classified as current liabilities if payment is due within one year
or less (or in the normal operating cycle of the business if
longer). If not, they are presented as non-current
liabilities.
Trade and other payables are
recognised initially at fair value, and subsequently measured at
amortised cost using the effective interest method. The carrying
amounts of trade and other payables are considered to be the same
as their fair values.
Share capital
Ordinary
shares
Ordinary shares are classified as
equity. Incremental costs directly attributable to the issue of
ordinary shares and share options are recognised as a deduction
from equity, net of any tax effects, from the proceeds.
Share-Based Payments
The Company operates an
equity-settled, share-based compensation plan, under which the
entity receives services from employees as consideration for equity
instruments (options) of the Company. The fair value of the
employee services received in exchange for the grant of the options
is recognised as an expense. The total amount to be expensed
is determined by reference to the fair value of the options
granted:
·
including any market performance conditions (for
example, an entity's share price);
·
excluding the impact of any service and non-market
performance vesting conditions (for example, profitability or sales
growth targets, or remaining an employee of the entity over a
specified time period); and
·
including the impact of any non-vesting conditions
(for example, the requirement for employees to save or holding
shares for a specific period of time).
At the end of each reporting period,
the group revises its estimates of the number of options that are
expected to vest based on the non-market vesting conditions and
service conditions. It recognises the impact of the revision to
original estimates, if any, in the income statement, with a
corresponding adjustment to equity.
In addition, in some circumstances
employees may provide services in advance of the grant date and
therefore the grant date fair value is estimated for the purposes
of recognising the expense during the period between service
commencement period and grant date.
When the options are exercised, the
company issues new shares. The proceeds received net of any
directly attributable transaction costs are credited to share
capital (nominal value) and share premium.
The grant by the Company of options
over its equity instruments to the employees of subsidiary
undertakings in the Group is treated as a capital contribution.
The fair value of employee services received, measured by
reference to the grant date fair value, is recognised over the
vesting period as an increase in investment in subsidiary
undertakings, with a corresponding credit to equity in the parent
entity accounts.
The social security contributions
payable in connection with the grant of the share options is
considered an integral part of the grant itself, and the charge
will be treated as a cash-settled transaction.
Revenue recognition
The group derives revenue from the
transfer of goods and services at a point in time and over time.
Revenue from external customers arise on the sales of software
licences, including associated maintenance, and consultancy
services.
Revenue from licence sales is measured at the
agreed transaction price at a point in time. A receivable is
recognised when access to the software is granted, since this is
the point in time that the consideration is unconditional because
only the passage of time is required before the payment is due.
Support and maintenance services are provided on the product
supplied; this is deemed to be a separately identifiable product
and is recognised over time. Revenue from consulting services are
recognised in the accounting period in which the services are
rendered.
Taxation
The Company is registered in Jersey,
Channel Islands and is taxed at the Jersey Company standard rate of
0%. However, the Company's subsidiaries are situated in
jurisdictions where taxation may become applicable to local
operations.
The major components of income tax
on profit or loss include current and deferred tax.
The tax currently payable is based
on the taxable profit for the period using the tax rates that have
been enacted or substantially enacted by the balance sheet date.
Taxable profit differs from the net profit as reported in the
income statement because it excludes items of income or expense
that are taxable or deductible in other years and it further
excludes items that are never taxable or deductible.
Deferred tax is provided in full,
using the liability method, on temporary differences arising
between the tax bases of assets and liabilities and their carrying
amounts in the Group financial statements. Deferred tax is
determined using tax rates that have been enacted or substantially
enacted at the balance sheet date and are expected to apply when
the related deferred income tax asset is realised of the deferred
tax liability is settled.
Deferred tax assets are only
recognised to the extent that it is probable that future taxable
profit will be available against which the asset can be utilised.
Deferred tax is charged or credited in the income statement, except
when it relates to items charged or credited to equity, in which
case the deferred tax is also dealt with in equity.
Critical accounting estimates and
judgements
Estimates and judgements are
continually evaluated and are based on historical experience and
other factors, including expectations of future events that are
believed to be reasonable under the circumstances.
Critical Accounting Estimates and
Assumptions
The Group makes estimates and assumptions
concerning the future. The resulting accounting estimates
will, by definition, seldom equal the related actual results.
The estimates and assumptions that have a significant risk of
causing a material adjustment to the carrying amounts of assets and
liabilities within the next financial year are discussed
below.
Fair value measurement
Management uses valuation techniques to
determine the fair value of assets held for sale. This involves
developing estimates and assumptions consistent with how market
participants would price the instrument. Management bases its
assumptions on best observable data available as far as possible.
Estimated fair values may vary from the actual prices that would be
achieved in an arm's length transaction at the reporting
date.
Critical judgments in applying the entity's accounting
policies
The following are the critical judgements that
the Directors have made in the process of applying the Group's
accounting policies and that have the most significant effect on
the amounts recognised in the financial statements.
Capitalisation of internally developed
software
Distinguishing the research and development
phases of the software suites and determining whether the
recognition requirements for the capitalisation of development
costs are met requires judgement. After capitalisation, management
monitors whether the recognition requirements continue to be met
and whether there are any indicators that capitalised costs may be
impaired.
Earnings per share
Basic and diluted
Earnings per share is calculated by
dividing the loss attributable to the equity holders of the Company
by the weighted average number of Ordinary shares in issue during
the period, excluding Ordinary shares purchased by the Company and
held as treasury shares.
|
Half year
ended
|
Audited
Full year
ended
|
Half
year
ended
|
|
30 Jun 2024
|
31 Dec
2023
|
30 Jun
2023
|
Loss
attributable to equity holders of the Company (£)
|
(274,309)
|
(623,816)
|
(300,473)
|
Loss from
discontinued operation attributable to equity holders of the parent
(£)
|
-
|
-
|
-
|
|
|
|
|
Weighted
average number of shares in issue (number)
|
214,158,129
|
183,700,212
|
182,621,390
|
Potentially
dilutive ordinary shares
|
24,922,974
|
6,792,500
|
6,792,500
|
For diluted
earnings per ordinary share
|
239,081,103
|
190,492,712
|
189,413,890
|
Loss per share (pence)
|
|
|
|
-From
continuing operations
|
(0.13)
|
(0.34)
|
(0.16)
|
-From
discontinued operations
|
(0.00)
|
(0.00)
|
(0.00)
|